Tag: Halogenated ether volatile general anesthetic

  • Sevoflurane

    Halogenated ether volatile general anesthetic

    A non-pungent fluorinated methyl isopropyl ether with a low blood-gas coefficient enabling fast induction and the dominant inhalational agent for pediatric mask induction.

    Abstract

    Sevoflurane (fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; CAS 28523-86-6; molecular formula C4H3F7O; molecular weight 200.05) is a fluorinated methyl isopropyl ether volatile anesthetic synthesized by Ross Terrell at Travenol Laboratories in 1968, brought to clinical use in Japan in 1990, and approved by the FDA in 1995 (Ultane, Sojourn). The minimum alveolar concentration (MAC) at age 40 is 1.8 percent in oxygen; the blood-gas partition coefficient is 0.65, faster than isoflurane (1.4) but slower than desflurane (0.42). The non-pungent character and absence of airway irritation make sevoflurane the agent of choice for inhalational induction of anesthesia, particularly in pediatric patients where intravenous access is established after induction. Mechanism parallels other halogenated ethers (GABA-A positive allosteric modulation, K2P channel activation, glycine and NMDA effects); the agent is achiral. Hepatic metabolism via CYP2E1 produces hexafluoroisopropanol and inorganic fluoride; the fluoride concentrations approach the historical nephrotoxic threshold associated with methoxyflurane (50 micromolar plasma) during prolonged exposure but published clinical data have not demonstrated nephrotoxicity in humans even with extended cases, attributed to the absence of intrarenal defluorination. The principal residual concern is degradation of sevoflurane in carbon dioxide absorbents (soda lime, Baralyme) at low fresh gas flows producing Compound A, which is nephrotoxic in rats but lacks demonstrated human renal injury within recommended fresh gas flow limits (1 to 2 L/min). Cardiovascular profile is favorable with preserved cardiac output, modest reduction in systemic vascular resistance, and minimal coronary steal physiology.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Desflurane

    Halogenated ether volatile general anesthetic

    The fully fluorinated successor to isoflurane with the lowest blood-gas coefficient of any clinical volatile, enabling the fastest induction and emergence in the class.

    Abstract

    Desflurane (1,2,2,2-tetrafluoroethyl difluoromethyl ether; CAS 57041-67-5; molecular formula C3H2F6O; molecular weight 168.04) is a fully fluorinated methyl ethyl ether developed by Ross Terrell at Anaquest in the 1980s and approved by the FDA in 1992 (Suprane). The minimum alveolar concentration (MAC) at age 40 is 6.0 percent in oxygen, the highest of the clinical volatile anesthetics; the blood-gas partition coefficient is 0.42, the lowest in the class, producing the fastest induction and emergence kinetics among approved inhalational agents. The high vapor pressure (664 mmHg at 20 degrees Celsius, near the boiling point of 23 degrees Celsius) requires a heated, pressurized vaporizer (Tec 6 or equivalent) rather than the variable-bypass design used for isoflurane and sevoflurane. Mechanism is the standard halogenated ether profile: GABA-A positive allosteric modulation, K2P channel activation, glycine and NMDA modulation. Hepatic metabolism is minimal (less than 0.02 percent of an absorbed dose), the lowest among inhalational anesthetics, virtually eliminating fluoride-related nephrotoxicity and trifluoroacetylated hepatotoxicity. The principal clinical limitations are airway irritation that precludes inhalational induction (coughing, breath-holding, laryngospasm at concentrations above 6 percent in non-anesthetized patients) and sympathetic stimulation with rapid concentration increases producing transient tachycardia and hypertension. The high MAC and high vapor pressure make desflurane the most expensive volatile per case at typical fresh gas flows, though low-flow techniques mitigate cost. Environmental concerns about high global warming potential (GWP100 approximately 2540 versus 130 for sevoflurane and 510 for isoflurane) have driven institutional restrictions on desflurane use in several health systems.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Enflurane

    Halogenated ether volatile general anesthetic

    The immediate predecessor to isoflurane in the Terrell ether series, marketed as Ethrane, displaced by isoflurane owing to electroencephalographic seizure activity at high concentrations.

    Abstract

    Enflurane (2-chloro-1,1,2-trifluoroethyl difluoromethyl ether; CAS 13838-16-9; molecular formula C3H2ClF5O; molecular weight 184.49) is a halogenated methyl ethyl ether developed by Ross Terrell at Ohio Medical Products in the structure-activity series that produced both enflurane (1963) and its structural isomer isoflurane (1965). Enflurane reached clinical use in 1972 (Ethrane) and was widely used through the 1980s before isoflurane displaced it. The minimum alveolar concentration (MAC) at age 40 is 1.68 percent in oxygen; the blood-gas partition coefficient is 1.9, intermediate between halothane and isoflurane. Mechanism parallels other volatile anesthetics (GABA-A, K2P, glycine, NMDA modulation). The principal clinical limitation is dose-dependent generation of high-amplitude epileptiform activity on electroencephalography, particularly at end-tidal concentrations above 2.5 percent and during hypocapnia, with occasional clinical seizures during deep anesthesia. The mechanism of enflurane epileptogenesis is incompletely characterized but appears to involve thalamocortical disinhibition at concentrations where cortical inhibition exceeds cortical excitatory tone. This electrophysiological profile contraindicates enflurane in patients with seizure disorders and contributed substantially to its displacement by isoflurane, the structural isomer with similar clinical profile but absent the epileptiform signal. Hepatic metabolism is approximately 2 to 5 percent (intermediate between halothane and isoflurane); fluoride generation is sufficient to raise plasma concentrations into the historically nephrotoxic range during very prolonged exposures. Cardiovascular effects include modest myocardial depression and dose-dependent vasodilation. Clinical use of enflurane has nearly disappeared in developed economies; it remains available as a research tool for halogenated ether structure-activity studies.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.

  • Isoflurane

    Halogenated ether volatile general anesthetic

    A halogenated methyl ethyl ether introduced in 1981 that remained the dominant inhalational anesthetic of the 1990s before sevoflurane and desflurane displaced it.

    Abstract

    Isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether; CAS 26675-46-7; molecular formula C3H2ClF5O; molecular weight 184.49) is a halogenated methyl ethyl ether volatile anesthetic introduced clinically by Ohio Medical Products in 1981. The minimum alveolar concentration (MAC) at 40 years of age is 1.15 percent in oxygen and 0.5 percent in 70 percent nitrous oxide. The blood-gas partition coefficient is 1.4, intermediate between halothane (2.4) and the modern agents desflurane (0.42) and sevoflurane (0.65); this corresponds to moderately fast induction and emergence relative to halothane but substantially slower than desflurane. Mechanism is multifactorial and incompletely characterized: principal targets include positive allosteric modulation of GABA-A receptors at sites distinct from benzodiazepine and barbiturate sites, two-pore domain potassium channel (TREK-1, TASK) activation, glycine receptor potentiation, and inhibition of NMDA glutamate currents at clinically relevant partial pressures. Cardiovascular effects include dose-dependent reduction in systemic vascular resistance and modest negative inotropy with preserved cardiac output through reflex tachycardia; coronary vasodilation has been studied for steal physiology but the clinical significance is limited. Respiratory effects include dose-dependent depression of tidal volume with compensatory tachypnea. Hepatotoxicity through trifluoroacetylated protein adduct formation occurs in 0.2 percent of metabolism (versus 20 percent for halothane) and the clinical incidence of immune-mediated hepatitis is correspondingly low. Used widely in veterinary anesthesia and in lower-resource settings where acquisition cost favors isoflurane over the newer agents.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.